Aadi Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Aadi Bioscience has a total shareholder equity of $68.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $85.7M and $16.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$62.62m |
Equity | US$68.87m |
Total liabilities | US$16.83m |
Total assets | US$85.70m |
Recent financial health updates
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Recent updates
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop
Jul 03Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)
May 10Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25Financial Position Analysis
Short Term Liabilities: AADI's short term assets ($77.3M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: AADI's short term assets ($77.3M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: AADI is debt free.
Reducing Debt: AADI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AADI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AADI is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 05:13 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aadi Bioscience, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Robert Burns | H.C. Wainwright & Co. |
Roger Song | Jefferies LLC |
Boris Peaker | TD Cowen |